Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection.
The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for today's and the future's portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces.
Jacoby
Edgar
E
Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. edgar.jacoby@pharma.novartis.com
Schuffenhauer
Ansgar
A
Popov
Maxim
M
Azzaoui
Kamal
K
Havill
Benjamin
B
Schopfer
Ulrich
U
Engeloch
Caroline
C
Stanek
Jaroslav
J
Acklin
Pierre
P
Rigollier
Pascal
P
Stoll
Friederike
F
Koch
Guido
G
Meier
Peter
P
Orain
David
D
Giger
Rudolph
R
Hinrichs
Jürgen
J
Malagu
Karine
K
Zimmermann
Jürg
J
Roth
Hans-Joerg
HJ
D000818:Animals; D001185:Artificial Intelligence; D020650:Combinatorial Chemistry Techniques; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D023281:Genomics / Q000379:methods*; D006801:Humans; D019151:Peptide Library
D019151:Peptide Library